Assuming this is who we think it is, this announcement is more significant for what is omitted.
No mention of the following.
- POC1 - Second paid collaborative project (second, paid) - Point of Care (POC) device - At least two of the scientists are ADO staff.
We also knew that M&G worked better than the incumbent technology in their test 12 months ago. And there have been no improvements in 12 month?? (hardly)
"the Feasibility Study is to assess whether Mix&Go provides an advantage in the development of a new device" Give us a break, this was known to be true a year ago!
Make no mistake, is announcement has all the hallmarks of being been heavily vetted (downplayed) by the" Global Healthcare Co.
BTW: Not having crack at GC here, he's doing a fantastic job.
Cheers Muz DYOR
ADO Price at posting:
6.3¢ Sentiment: LT Buy Disclosure: Held
